Why is myocardial viability testing required before coronary artery bypass grafting (CABG)?

Myocardial Viability Testing Before CABG: Why It's Necessary

Myocardial viability testing before CABG is necessary primarily to identify patients with poor left ventricular function who have substantial regions of hibernating myocardium that would benefit from revascularization, particularly when heart failure symptoms predominate over angina. This testing helps distinguish between irreversibly scarred myocardium and viable but dysfunctional tissue that can recover function after revascularization.

The Core Rationale

The fundamental concept is that patients with ischemic cardiomyopathy have heterogeneous myocardium—a mixture of normal, stunned, hibernating, and scarred tissue 1. Viability testing becomes essential when deciding whether to operate on patients with prominent heart failure symptoms and minimal angina, as the decision should be based on objective evidence of hibernating myocardium 1.

When Viability Testing Is Most Critical

According to ACC/AHA guidelines, viability assessment is specifically indicated for:

• Patients with poor LV function (EF <0.50) and prominent CHF symptoms with minimal angina 1, 2
• Patients without typical anatomic patterns (left main, 3-vessel disease, or proximal LAD involvement) who might still benefit from revascularization 1
• Patients with 1- or 2-vessel disease without proximal LAD stenosis but with potential for large areas of viable myocardium 2

The guidelines establish a clear hierarchy: CABG is Class IIa (reasonable) for poor LV function WITH significant viable noncontracting revascularizable myocardium, but Class III (not recommended) for poor LV function WITHOUT evidence of significant revascularizable viable myocardium 1.

The Clinical Decision Algorithm

Step 1: Assess Anatomic Pattern

If the patient has:

• Left main stenosis
• Left main equivalent (proximal LAD + proximal circumflex ≥70%)
• Proximal LAD with 2- or 3-vessel disease

→ Proceed with CABG regardless of viability testing (Class I indication) 1, 2

Step 2: If Non-Standard Anatomy

Evaluate clinical presentation:

• Intermittent ischemia with minimal CHF → CABG appropriate without mandatory viability testing 1
• Prominent CHF with minimal angina → Viability testing becomes essential 1

Step 3: Viability Testing Results Guide Decision

• Large areas of viable myocardium → CABG becomes Class I recommendation 2
• Small areas of viable myocardium → CABG is Class III (not recommended) 2
• No demonstrable ischemia → CABG is Class III (not recommended) 2

Important Caveats and Pitfalls

The Evidence Controversy

A critical caveat: Recent high-quality evidence challenges the traditional viability paradigm. The STICH trial substudy (2019) with 10.4 years follow-up found that myocardial viability did NOT predict differential benefit from CABG over medical therapy (P=0.34 for interaction) 3. This landmark study showed CABG improved survival regardless of viability status, though viable myocardium was associated with improved LV function independent of treatment.

Similarly, the 2024 ESC guidelines note that "the heterogeneous designs of studies, statistical underpower of subgroup analyses, and heterogeneous methods of viability assessments leave many open questions on how viability should be defined" 4. The REVIVED-BCIS2 trial further demonstrated no benefit of PCI in patients with viable myocardium and severe LV dysfunction.

Current Guideline Status

The 2016 ESC heart failure guidelines and 2018 ESC revascularization guidelines downgraded viability assessment to Class IIb Level B (may be considered), reflecting this uncertainty 5. The 2024 ESC guidelines acknowledge that "the classical binary definition of myocardial viability may benefit from more contemporary paradigms" 4.

Practical Implications

Despite the controversy, viability testing remains valuable for:

1. Risk stratification: Larger amounts of non-viable myocardium predict worse outcomes regardless of revascularization 4

2. Selecting revascularization strategy: Distinguishing between PCI versus CABG in complex multivessel disease when viable myocardium distribution matters 5

3. Avoiding futile surgery: Patients with extensive scarring and no viable myocardium face high operative risk without potential benefit 1, 2

4. Anatomic alignment: Ensuring viable myocardial regions are perfused by coronary arteries of sufficient size and location to be reasonable bypass targets 1

The Bottom Line for Clinical Practice

In 2024, viability testing should NOT be used as the sole determinant for CABG candidacy in ischemic cardiomyopathy. Instead, integrate multiple factors:

• Coronary anatomy (multivessel disease, especially with proximal LAD involvement favors CABG) 6, 7, 8
• Clinical presentation (angina and inducible ischemia support intervention) 1
• LV end-systolic volume and overall cardiac remodeling 4
• Surgical risk assessment (STS score, comorbidities) 8, 6
• Patient age and functional status 9

When viability testing IS performed, use it primarily to avoid operating on patients with predominantly scarred myocardium who lack sufficient viable tissue to justify the surgical risk 1, 2. The presence of viability supports the decision but its absence should not automatically exclude appropriate surgical candidates with suitable anatomy and symptoms 3, 10.

The most recent evidence suggests that CABG benefits in ischemic cardiomyopathy derive more from preventing future ischemic events and providing electrical stability than from recovering hibernating myocardium 9.